Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Refametinib, a MEK Inhibitor, as Second-line Treatment in Advanced Biliary Tract Adenocarcinoma

NCT02346032 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT02346032
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02346032 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Refametinib, a MEK Inhibitor, as Second-line Treatment in Advanced Biliary Tract Adenocarcinoma
Lead sponsor
Samsung Medical Center
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2015
Completion date
October 13, 2016
Enrollment
4 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract cancer